Trial Profile

PRISM: determination of the performance characteristics of ReQuest in practice in the stepped down management of GORD [gastro-oesophageal reflux disease]

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pantoprazole (Primary)
Indications Gastro-oesophageal reflux
Focus Therapeutic Use
Acronyms PRISM
Sponsors Fougera Pharmaceuticals; Takeda

Most Recent Events

04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
07 Jul 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com